一种抗菌,多功能纳米凝,用于有效治疗中性友性喘
Xu Zuo1, Xiaoping Guo1, Dan Zhao2
1The Medical Basic Research Innovation Center of Airway Disease in North China, Ministry of Education, and College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
概括
新的纳米凝通过向细菌感染和炎症来对抗中性友性喘. 在小鼠模型中,ECAT纳米凝有效降低了NTHi的扩散和气道炎症,提供了一个有前途的治疗策略.
科学领域:
- 生物材料科学 生物材料科学
- 呼吸系统医学 呼吸系统医学
- 传染性疾病 传染性疾病
背景情况:
- 喘是一种慢性呼吸道疾病,具有严重的,抗皮质类固醇的中性粒细胞亚型.
- 非类型性Haemophilus influenzae (NTHi) 感染越来越多地与中性友性喘有关,症状恶化和医疗负担增加.
- 目前对严重喘的治疗方法,特别是中性友好型表型,需要新的治疗方法.
研究的目的:
- 开发和评估用于治疗中性友性喘的新型复合纳米凝.
- 评估纳米凝对关键呼吸道病原体的抗菌疗效.
- 在中性性喘的临床前模型中研究纳米凝的抗炎和治疗潜力.
主要方法:
- 通过离子交叉连接素移植酸盐 (CS-Arg) 与三二碳乙基 (TCEP) 并加入聚-ε-L-氨酸 (ε-PLL) 来制造ECAT纳米凝.
- 在实验室中评估ECAT纳米凝抗菌活性对NTHi,金黄色葡萄球菌和大肠杆菌,以及粘真菌聚合物的抑制.
- 在卵胺 (OVA) /NTHi诱导的中性友性喘小鼠模型中的ECAT纳米凝的体内评估,评估炎症细胞数量,呼吸道过敏反应和炎症.
主要成果:
- 在实验室中,ECAT纳米凝显示出对NTHi,S. aureus和E. coli增殖的强有力的抑制作用.
- 在实验室中,ECAT纳米凝有效地抑制了粘素聚合物的形成,这表明呼吸道疾病中粘液破坏的可能性.
- 雾化ECAT纳米凝的施用显著降低了中性粒细胞和炎症细胞,逆转了气道过敏反应,并缓解了中性粒细胞喘小鼠的炎症.
结论:
- ECAT纳米凝是一种可行的抗感染和抗炎治疗策略.
- 开发的纳米凝显示出对中性友性喘的临床治疗有很大的潜力.
- 这项研究强调了针对复杂呼吸系统疾病的基于纳米凝的向治疗的前景.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
271
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
271
Antiasthma Drugs: Leukotriene Modifiers
276
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
276


